Brainomix, an AI medical imaging company focused on stroke and lung fibrosis, announced a £4.8 million extension to its Series C financing, bringing the total raised in the round to £18.8 million, or approximately $25.4 million. The company had previously secured £14 million in March 2025.
The extension round was led by existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, with participation from new U.S.-based investor Modi Ventures.
With established operations in the United States and a portfolio of FDA-cleared AI imaging solutions, Brainomix plans to use the additional capital to deepen its U.S. market presence. The funding will support broader deployment of its Brainomix 360 Stroke and Brainomix 360 e-Lung platforms across hospitals, while also strengthening customer support in the U.S. and Europe and accelerating product innovation.
Brainomix 360 Stroke is positioned as a fully automated AI imaging platform for acute stroke assessment across the patient pathway, supporting faster and more confident treatment and transfer decisions. The Brainomix 360 e-Lung platform uses AI-driven CT biomarkers to help identify, monitor, and predict disease progression in pulmonary fibrosis, with a focus on enabling earlier diagnosis and treatment.
Founded as a spinout from the University of Oxford, Brainomix operates in more than 20 countries, with offices in the UK, Ireland, and the United States. The company focuses on enabling precision medicine through AI-powered imaging tools designed to improve clinical decision-making and patient outcomes.
KEY QUOTES:
“This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.”
Dr. Michalis Papadakis, CEO And Co-Founder Of Brainomix
“Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centers. With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes. We are pleased to join as a new investor and look forward to supporting the company as it expands in the U.S. and accelerates adoption of technologies that meaningfully improve patient outcomes.”
Sahir Ali, Founder And General Partner Of Modi Ventures
